NASDAQ
Humacyte, Inc. (HUMA) has a price/sales ratio of 74.54x as of Friday, May 22, 2026. This represents a 19.06% decrease compared to its 12-month average of 92.10x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.